Alliancebernstein L.P. Erasca, Inc. Transaction History

Alliancebernstein L.P.

$287 Billion
Q3 2024

A detailed history of Alliancebernstein L.P. transactions in Erasca, Inc. stock. As of the latest transaction made, Alliancebernstein L.P. holds 154,490 shares of ERAS stock, worth $417,123. This represents 0.0% of its overall portfolio holdings.

Number of Shares

154,490

Previous 154,490 -0.0%

Holding current value

$417,123

Previous $364,000 15.66%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$1.79 - $2.63 $64,762 - $95,153	36,180 Added 30.58%	154,490 $364,000
Q3 2023 Nov 14, 2023	BUY	$1.97 - $2.91 $12,056 - $17,809	6,120 Added 5.46%	118,310 $233,000
Q2 2023 Aug 15, 2023	SELL	$2.57 - $3.3 $212,025 - $272,250	-82,500 Reduced 42.38%	112,190 $309,000
Q1 2023 May 15, 2023	SELL	$2.74 - $4.44 $4.93 Million - $7.99 Million	-1,800,275 Reduced 90.24%	194,690 $586,000
Q4 2022 Feb 14, 2023	SELL	$3.89 - $8.57 $8.36 Million - $18.4 Million	-2,148,159 Reduced 51.85%	1,994,965 $8.6 Million
Q3 2022 Nov 15, 2022	BUY	$5.82 - $10.68 $449,856 - $825,510	77,295 Added 1.9%	4,143,124 $32.3 Million
Q2 2022 Aug 15, 2022	BUY	$4.58 - $8.72 $3.08 Million - $5.86 Million	672,098 Added 19.8%	4,065,829 $22.6 Million
Q1 2022 May 13, 2022	BUY	$8.6 - $15.48 $1.18 Million - $2.12 Million	137,085 Added 4.21%	3,393,731 $29.2 Million
Q4 2021 Feb 14, 2022	BUY	$12.51 - $22.75 $9.13 Million - $16.6 Million	729,615 Added 28.87%	3,256,646 $50.7 Million
Q3 2021 Nov 10, 2021	BUY	$17.43 - $24.34 $44 Million - $61.5 Million	2,527,031 New	2,527,031 $53.6 Million

Others Institutions Holding ERAS

# of Institutions

141

Shares Held

229M

Call Options Held

28.7K

Put Options Held

117K

View Full List

About Erasca, Inc.

Ticker ERAS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 122,147,000
Market Cap $330M
Description
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...

More about ERAS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

News

Stay updated on Alliancebernstein L.P. with notifications on news.

Account

Alliancebernstein L.P. Erasca, Inc. Transaction History